MedTrace Logo

A Study Of The Usage Of Statins In A Community Heart Failure Population

NCT00795912 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2008-11-21

No results posted yet for this study

Summary

Inflammation and fibrosis may be important contributors to worsening heart failure. As well as lowering cholesterol, statins are also known to reduce inflammatory markers such as C-reactive protein which are elevated in severe heart failure. Therefore, this project will evaluate the benefit, if any, of statins on markers of heart structure and function, on inflammatory markers and markers of fibrosis in patients with normal cholesterol.

Conditions

Interventions

DRUG

Atorvastatin

atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months

Sponsors & Collaborators

  • University of Dublin, Trinity College

    collaborator OTHER

  • University College Dublin

    collaborator OTHER

  • University College Cork

    collaborator OTHER

  • St Vincent's University Hospital, Ireland

    lead OTHER

Principal Investigators

  • Mark T Ledwidge, PhD · St Vincent's University Hospital

  • Kenneth M McDonald, MD · St Vincent's University Hospital

  • Esam Abulhul, MB · St Vincents University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2005-11-30
Completion
2008-01-31

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00795912 on ClinicalTrials.gov